Letter to Shareholders

To Our Shareholders and Employees:
In the history of every company, there are defining moments: new product introductions, compelling clinical results, exciting new ventures, seized opportunities.

We find ourselves on the cusp of an opportunity that will not only redefine us as a company, but that also promises to redefine an entire industry. Our TAXUS™ paclitaxel-eluting stent system has already been launched in Europe and other international markets, and we plan to launch it later this year in the United States. The TAXUS program, along with the continued success of our many other technologies, positions Boston Scientific for leadership today and for years to come.